Plain-English translation of NCT04420702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new type of MRI imaging called Diffusion Basis Spectrum Imaging (DBSI) to see if it can detect prostate cancer more accurately than current methods. The scan is non-invasive, meaning there are no needles or surgical procedures — just an imaging test. Researchers hope this could eventually help men avoid unnecessary biopsies or catch cancer earlier.
Many men with elevated PSA levels (a blood marker) end up needing biopsies, which can be uncomfortable and sometimes don't find cancer when it's actually there. This trial exists to see whether the new imaging test could be a more accurate and gentler way to detect clinically significant prostate cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have an MRI scan with the new DBSI imaging analysis. Within 12 weeks of your scan, you will also have a standard prostate biopsy as part of your usual care — this allows doctors to compare how well the new imaging test worked. If you go on to have prostate surgery as part of your treatment, your surgical specimen may also be scanned with the new imaging to help researchers refine the technology.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States